FR2839646B1 - Utilisation de derives de quinoleine a effet anti-integrase et ses applications - Google Patents

Utilisation de derives de quinoleine a effet anti-integrase et ses applications

Info

Publication number
FR2839646B1
FR2839646B1 FR0206126A FR0206126A FR2839646B1 FR 2839646 B1 FR2839646 B1 FR 2839646B1 FR 0206126 A FR0206126 A FR 0206126A FR 0206126 A FR0206126 A FR 0206126A FR 2839646 B1 FR2839646 B1 FR 2839646B1
Authority
FR
France
Prior art keywords
applications
quinoline derivatives
integrase
effect
integrase effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0206126A
Other languages
English (en)
Other versions
FR2839646A1 (fr
Inventor
Aurelie Mousnier
Catherine Dargemont
Sabine Bonnenfant
Herve Leh
Jean Francois Mouscadet
Fatima Zouhiri
Angelo Jean D
Didier Desmaele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioalliance Pharma SA
Original Assignee
Bioalliance Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0206126A priority Critical patent/FR2839646B1/fr
Application filed by Bioalliance Pharma SA filed Critical Bioalliance Pharma SA
Priority to CA002489102A priority patent/CA2489102A1/fr
Priority to AU2003251047A priority patent/AU2003251047A1/en
Priority to PCT/FR2003/001487 priority patent/WO2003096965A2/fr
Priority to EP03752821A priority patent/EP1507532A2/fr
Priority to JP2004504964A priority patent/JP2005531554A/ja
Priority to US10/514,631 priority patent/US7479497B2/en
Priority to IL16526903A priority patent/IL165269A0/xx
Publication of FR2839646A1 publication Critical patent/FR2839646A1/fr
Priority to US12/042,628 priority patent/US20080161350A1/en
Application granted granted Critical
Publication of FR2839646B1 publication Critical patent/FR2839646B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
FR0206126A 2002-05-17 2002-05-17 Utilisation de derives de quinoleine a effet anti-integrase et ses applications Expired - Fee Related FR2839646B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR0206126A FR2839646B1 (fr) 2002-05-17 2002-05-17 Utilisation de derives de quinoleine a effet anti-integrase et ses applications
AU2003251047A AU2003251047A1 (en) 2002-05-17 2003-05-15 Use of quinoline derivatives with anti-integrase effect and applications thereof
PCT/FR2003/001487 WO2003096965A2 (fr) 2002-05-17 2003-05-15 Derives de quinoleine a effet anti-integrase et leurs applications comme antiviraux
EP03752821A EP1507532A2 (fr) 2002-05-17 2003-05-15 Utilisation de derives de quinoleine a effet anti-integrase et ses applications
CA002489102A CA2489102A1 (fr) 2002-05-17 2003-05-15 Derives de quinoleine a effet anti-integrase et leurs applications comme antiviraux
JP2004504964A JP2005531554A (ja) 2002-05-17 2003-05-15 抗インテグラーゼ作用をもつキノリン誘導体類の利用およびそれらの応用
US10/514,631 US7479497B2 (en) 2002-05-17 2003-05-15 Use of quinoline derivatives with anti-integrase effect and applications thereof
IL16526903A IL165269A0 (en) 2002-05-17 2003-05-15 Use of quinoline derivatives with anti-integrase effect and applications thereof
US12/042,628 US20080161350A1 (en) 2002-05-17 2008-03-05 Use of quinoline derivatives with anti-integrase effect and applications thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0206126A FR2839646B1 (fr) 2002-05-17 2002-05-17 Utilisation de derives de quinoleine a effet anti-integrase et ses applications

Publications (2)

Publication Number Publication Date
FR2839646A1 FR2839646A1 (fr) 2003-11-21
FR2839646B1 true FR2839646B1 (fr) 2008-04-11

Family

ID=29286592

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0206126A Expired - Fee Related FR2839646B1 (fr) 2002-05-17 2002-05-17 Utilisation de derives de quinoleine a effet anti-integrase et ses applications

Country Status (8)

Country Link
US (2) US7479497B2 (fr)
EP (1) EP1507532A2 (fr)
JP (1) JP2005531554A (fr)
AU (1) AU2003251047A1 (fr)
CA (1) CA2489102A1 (fr)
FR (1) FR2839646B1 (fr)
IL (1) IL165269A0 (fr)
WO (1) WO2003096965A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280849A1 (en) * 2005-06-01 2008-11-13 Herve Leh Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents
KR20100108337A (ko) * 2007-11-15 2010-10-06 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
ES2381234T3 (es) * 2007-11-15 2012-05-24 Gilead Sciences, Inc. Inhibidores de la replicación del virus de la inmunodeficiencia humana
WO2009062308A1 (fr) * 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibiteurs de la réplication du virus de l'immunodéficience humaine
CA2707418C (fr) * 2007-11-16 2013-11-19 Boehringer Ingelheim International Gmbh Inhibiteurs de la replication du virus de l'immunodeficience humaine
CA2793959C (fr) 2010-03-25 2019-06-04 Oregon Health & Science University Glycoproteines du cmv et vecteurs recombines
SG186821A1 (en) * 2010-07-02 2013-02-28 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
UY33480A (es) 2010-07-02 2012-02-29 Gilead Sciences Inc Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
ES2615734T3 (es) 2011-04-21 2017-06-08 Gilead Sciences, Inc. Compuestos de benzotiazol y su uso farmacéutico
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
BR112014013224B1 (pt) 2011-11-30 2023-03-07 Emory University Inibidores de jak antivirais úteis no tratamento ou prevenção de infecções retrovirais e outras infecções virais
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
WO2013103724A1 (fr) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Dérivés d'acide 2-(tert-butoxy)-2-(7-méthylquinoléin-6-yl)acétique pour traiter le sida
BR112014018990A8 (pt) 2012-04-20 2017-07-11 Gilead Sciences Inc Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
FR2830863B1 (fr) * 2001-10-12 2004-01-30 Bioalliance Pharma Derives de quinoleine, procede de synthese, et medicaments renfermant ces derives

Also Published As

Publication number Publication date
FR2839646A1 (fr) 2003-11-21
US20050261336A1 (en) 2005-11-24
CA2489102A1 (fr) 2003-11-27
WO2003096965A2 (fr) 2003-11-27
AU2003251047A8 (en) 2003-12-02
WO2003096965A3 (fr) 2004-04-22
US20080161350A1 (en) 2008-07-03
AU2003251047A1 (en) 2003-12-02
US7479497B2 (en) 2009-01-20
IL165269A0 (en) 2005-12-18
JP2005531554A (ja) 2005-10-20
EP1507532A2 (fr) 2005-02-23

Similar Documents

Publication Publication Date Title
FI20021045A (fi) Paikannusepävarmuuden mittoja ja niiden sovelluksia
DE60319430D1 (de) R- und fgfr-inhibitoren
DE60310103D1 (de) Automatische detektion und überwachung von physischer bewegung an der äusseren begrenzung
ATE422495T1 (de) Antibakterielle naphthydrin- und quinolinderivate
FR2848115B1 (fr) Composition de bacteries et son utilisation
DE60326611D1 (de) N und dergleichen
NO20052278L (no) Piperazinyl- og diazapanyl-benzamider og -benztioamider
FR2839646B1 (fr) Utilisation de derives de quinoleine a effet anti-integrase et ses applications
SE0203190L (sv) Anordning och förfarande
DK1675852T3 (da) Heterocykliske 7-amino-alkylidenyl-quinoloner og -naphthyridoner
DE60321152D1 (de) Elastisches kernmantelgarn und elastische webmaschenware
DE50304938D1 (de) Einzugs- und Pflückeinrichtung
NO20033471D0 (no) utvidbar anordning samt fremgangsmåte vedrörende samme
DE60334199D1 (de) Acrylhaftklebstoff und haftklebeband
DE60331556D1 (de) Beschichtete kapillar-elektrophoreseröhren und system
DE50313181D1 (de) Alkyl-und/oder alkylenoligoglycosid-betainesterquats
FR2834292B1 (fr) Extraits bacteriens de sangsues a effet notamment thrombolytique
DE602004022445D1 (de) Dro-1h-pyrazol-derivaten mit cb1-antagonistischer wirkung und lipase-hemmern
FI20021614A0 (fi) Säilytysväline ja sen käyttö
FIU20020382U0 (fi) Kantopakkaus ja kantoelin
SE0201130D0 (sv) Knockout and their use
FR2834293B1 (fr) Extraits de sangsues a effet psychosomatique
FI20021348A0 (fi) Päällystysmenetelmä ja -laite
ES1058979Y (es) Cable autoadhesivo y similares
FR2855053B1 (fr) Utilisation de l'hydroxyzine et de ses derives

Legal Events

Date Code Title Description
TQ Partial transmission of property
RM Correction of a material error
ST Notification of lapse

Effective date: 20130131